Pravacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pravacor

Property Description
Active Ingredient Pravastatin sodium
Form Tablets, Oral formulation
Pharmacological Class HMG-CoA reductase inhibitor (Statin)
Common Use Lipid management
Origin Synthetic compound

Pravacor is a medication containing the active ingredient pravastatin sodium, a synthetic compound that is classified as a statin. It is provided as an oral formulation in the form of tablets and is designated as a prescription drug. The core identity of this substance, Pravastatin, places it within the major pharmacological class known as HMG-CoA reductase inhibitors, defining its intended biological function.


Pravastatin's Pharmacological Classification and Type

Pravastatin is an antihyperlipidemic agent whose primary mechanism involves targeting a key enzyme in the body. It is a selective inhibitor of HMG-CoA reductase, the enzyme responsible for cholesterol production in the liver. The drug's action is characterized by its ability to reduce the synthesis of cholesterol within the body.

Pravastatin is structurally classified as a hydrophilic statin. This specific characteristic means its action is generally more focused on the liver tissue, which can differentiate its pharmacological profile compared to more lipophilic agents in the same class. This distinction in tissue selectivity characterizes its pharmacological profile.


Pravacor's General Purpose

The general purpose of Pravacor is comprehensive lipid management, specifically focused on controlling and reducing harmful Low-Density Lipoprotein (LDL) cholesterol in the bloodstream. By inhibiting the internal synthesis of cholesterol, the body's natural processes are enhanced to clear LDL from the circulation.

Statins, including pravastatin, are used to lower LDL cholesterol levels. For patients, this medicine provides a pharmacological method to control elevated levels of harmful cholesterol, contributing to the overall stability of the cardiovascular system. The drug is utilized for the management of high lipid concentrations through this specific enzyme inhibition.

Regulatory References

  1. National Institutes of Health (NIH) confirms its classification

What side effects are possible with Pravacor?

Possible Side Effects and Safety Information

The official safety profile for pravastatin sodium, the active ingredient in Pravacor, is organized according to the type and frequency of documented adverse reactions, as established by regulatory authorities. The adverse reactions are classified across several System-Organ Classes, including Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.


Frequency and Common Reactions

Adverse effects are categorized by frequency (e.g., Common, Uncommon, Rare). Common reactions documented in official labeling include musculoskeletal pain, headache, nausea/vomiting, diarrhea, and upper respiratory tract infection.

Serious Adverse Reactions

Serious reactions are defined within the labeling, and these include Myopathy and Rhabdomyolysis, which involves skeletal muscle breakdown and can be associated with acute renal failure. Reports of Immune-Mediated Necrotizing Myopathy (IMNM) and rare cases of fatal and non-fatal Hepatic Failure are also explicitly documented. Pancreatitis is listed among the post-marketing adverse reactions.


Population-Specific Constraints

Official labeling defines strict constraints for use, including a contraindication during pregnancy and lactation. Individuals with active liver disease or persistent, unexplained elevations of liver enzymes (serum transaminases) are also formally contraindicated. Regulatory documents identify advanced age and renal impairment as predisposing factors for developing skeletal muscle effects. The safety profile also notes that cognitive impairment, such as memory loss, is generally reversible upon discontinuation of therapy, and that interstitial lung disease has been associated with long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Pravacor (pravastatin) overdose indicates that experience with acute overdosage in clinical trials is limited. The few reported cases have involved symptoms such as diarrhea, nausea, and vomiting.

The official overdose profile is structured around the potential for serious adverse reactions associated with high exposure to the medication.


Management and Serious Outcome Risk

The treatment for a pravastatin overdose is designated as symptomatic and supportive. Due to the drug's high protein binding, hemodialysis is unlikely to be of benefit in the management of an overdose.

The most critical risk is the potential for myopathy (muscle damage) and its severe form, rhabdomyolysis, which can lead to acute renal failure. This risk is generally elevated with higher doses and in vulnerable populations, including the elderly and those with renal impairment.


Required Emergency Actions

If an overdose of Pravacor is suspected, it is advised to contact a Poison Control Center or Emergency Room at once.

Patients taking pravastatin must be aware of the signs of myopathy and are instructed to promptly report any unexplained muscle pain, tenderness, or weakness, especially if these symptoms are accompanied by malaise or fever. These manifestations may indicate a serious reaction that necessitates immediate medical evaluation and potential discontinuation of the drug.

Therapeutic Uses of Pravacor

Pravacor is a prescription medication used to assist in the management of elevated levels of cholesterol and triglycerides in the bloodstream. It is primarily utilized as an adjunct to lifestyle changes, such as diet and exercise, when those measures alone have not been adequate to achieve health goals. The medication is indicated for conditions including primary hypercholesterolemia and mixed dyslipidemia.

In addition to addressing lipid levels, Pravacor may assist in reducing the likelihood of major cardiovascular events. This benefit applies to patients with clinically evident coronary heart disease (CHD), as well as those who are at an increased risk. The use of this medication may help to slow the progression of coronary atherosclerosis.


Quick Fact: Relief for High Cholesterol Pravacor is integrated into a complete care plan to support the patient in reaching and maintaining target blood lipid levels.

Eligibility and Restrictions for Use

Who Can and Cannot Use Pravacor (Pravastatin Sodium)

Eligibility for Pravacor is strictly defined by regulatory authorities and centers on absolute contraindications, age, and pre-existing health conditions.


Populations Explicitly Contraindicated (Must Not Use)

Category Regulatory Status
Active Liver Disease Contraindicated
Hypersensitivity Contraindicated to pravastatin or any component
Pregnancy Contraindicated
Lactation (Breastfeeding) Contraindicated

Eligibility Based on Age and Organ Function

Category Eligibility Rule
Adults Approved under standard labeled conditions
Children 8–18 Years Approved only for specific conditions (e.g., HeFH) and criteria
Children Under 8 Years Use not established (not recommended)
Severe Renal Impairment Restricted use; requires caution and lower starting dose
Significant Hepatic Impairment Restricted use; requires caution and lower starting dose

Use also requires caution in individuals with predisposing factors for myopathy, such as hereditary muscular disorders or uncontrolled hypothyroidism. This information is based solely on official government labeling and prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pravastatin's official interaction profile is defined by combinations that either increase the risk of muscle toxicity or alter drug exposure based on regulatory documentation.

Interaction-Related Restrictions

  • Prohibited Combinations: Co-administration with Systemic Fusidic Acid is prohibited due to the risk of rhabdomyolysis; pravastatin therapy must be suspended during treatment with fusidic acid. Concomitant use with Gemfibrozil is also officially not recommended.
  • Timing Separation: Bile acid sequestrants (e.g., Cholestyramine) reduce pravastatin absorption. To mitigate this effect, pravastatin must be taken at least one hour before or four hours after the sequestrant.

Clinically Significant Exposure Alterations

Interacting Substance Official Interaction Statement
Cyclosporine Increases pravastatin exposure (AUC/Cmax), requiring a maximum dose of 20 mg once daily.
Clarithromycin/Erythromycin Increases pravastatin exposure, requiring a maximum dose of 40 mg once daily.

Pharmacodynamic Risk

Interactions that increase the documented risk of adverse skeletal muscle effects include co-administration with other fibrates (e.g., Fenofibrate), Colchicine, and lipid-modifying doses of Niacin (≥1 g/day). Advanced age and renal impairment are noted as population-specific factors that may increase the general risk of muscular toxicity when co-administered with interacting agents. No clinically significant interaction with grapefruit juice is documented in official labeling.

Mechanism of Action

How Pravacor Works

The physiological effects of Pravacor (pravastatin) are primarily driven by its mechanism as a reversible competitive inhibitor of the enzyme HMG-CoA reductase. This enzyme dictates the rate-limiting step in the Mevalonate pathway of cholesterol biosynthesis, acting predominantly within the liver cells (hepatocytes).


️ Systemic Upregulation of LDL Clearance

Inhibition of the enzyme reduces the intracellular cholesterol pool, which triggers a powerful feedback cascade involving the SREBP transcription factors. This mechanism leads to the upregulation of LDL Receptors on the surface of the hepatocytes. The resulting increase in receptor density enhances the liver's ability to actively capture and remove circulating LDL particles from the bloodstream, leading to enhanced systemic clearance and a measurable change in plasma lipoprotein concentration.


️ Pleiotropic Modulation of Vascular Function

The inhibition of this pathway also reduces the production of non-sterol intermediates, such as isoprenoids. This secondary action influences vascular cell signaling (pleiotropic effect), affecting changes in endothelial function and influencing the cellular processes involved in arterial plaque morphology.

Dosage and Administration Information

How to Use Pravacor

This section describes the administration and dosing guidelines for Pravastatin (Pravacor), focusing strictly on procedural usage and schedules.


Administration and Standard Dosing

Pravacor is administered orally as a tablet. The medication is prescribed for a once-daily intake and may be taken at any time of the day, with or without food.

For most adults, the usual starting dose is 40 mg once daily. Dosing is adjusted by the prescribing professional based on the individual's cholesterol response and must adhere to the standard adult maximum recommended daily dose of 80 mg. Dose adjustments are typically made after an interval of four weeks or more to allow the full effect of the current dose to be assessed.


Population-Specific Use and Special Timing

Dosing protocols include specific starting points for certain populations. For adults with severe renal impairment, a lower starting dose of 10 mg once daily is specified, with a maximum of 40 mg daily. Pediatric dosing is also defined, with patients aged 8 to 13 years typically starting at 20 mg and older adolescents (14 to 18 years) starting at 40 mg.

Administration requires specific timing when used with a bile acid resin (e.g., cholestyramine), which is commonly used to lower cholesterol. In this scenario, Pravastatin must be taken one hour before or four or more hours after the bile acid resin dose. This pattern of use is intended for long-term, continuous therapy as an adjunct to a cholesterol-lowering diet. If a dose is missed, individuals should resume the once-daily schedule with the next dose and avoid taking two doses at the same time.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical trials have evaluated the effect of pravastatin (sold under the brand name Pravacor) across various patient populations, primarily focusing on lipid management and cardiovascular event reduction.

Primary Lipid Outcomes

Across multiple randomized controlled trials (RCTs), pravastatin was consistently associated with reductions in low-density lipoprotein cholesterol (LDL-C) and total cholesterol. Specifically, dose-response studies found that pravastatin doses ranging from 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%.

There was also a reported modest, dose-dependent decrease in triglycerides and an increase in high-density lipoprotein cholesterol (HDL-C) levels, although the effect on HDL-C was generally considered weak or non-dose-dependent in some analyses.

Cardiovascular Event Reduction

Long-term studies have investigated the relationship between pravastatin use and clinical outcomes:

  • Secondary Prevention: In patients with established coronary heart disease (CHD), studies indicated that pravastatin was associated with a reduction in the risk of myocardial infarction (MI), revascularization procedures, and cardiovascular mortality.
  • Elderly Population: The PROSPER trial, which included individuals aged 70–82 years at risk of vascular disease, reported that pravastatin was associated with a reduction in the risk of coronary disease over an average follow-up of 3.2 years.

Safety and Emerging Research

Adverse event data collected in short-term trials identified musculoskeletal pain, headache, and gastrointestinal issues as the most commonly reported side effects. Ongoing research has examined the compound's use in specific, non-lipid-related areas, including small pilot studies assessing its safety and potential utility in pregnant women at high risk for preeclampsia, and its investigational use for radiation-induced fibrosis.

Frequently Asked Questions (FAQ)

Common questions about Pravacor (FAQ)


Q: What are the main medical conditions Pravacor is approved to treat?

Official product information states that Pravacor is approved to help reduce high levels of total cholesterol, LDL-C (bad cholesterol), and triglycerides. Additionally, it is used to reduce the overall risk of certain cardiovascular events. This includes reducing the chance of a first or subsequent heart attack and the need for revascularization procedures.


Q: Do I need to maintain a low-fat diet and exercise while taking Pravacor?

According to the official product information, Pravacor is intended to be used as an adjunct to other treatments, meaning it supports other efforts. These supporting efforts typically include maintaining a cholesterol-lowering diet, exercising regularly, and managing weight. The medication is not meant to replace these important lifestyle modifications.


Q: What are the signs of a serious allergic reaction to Pravacor?

Regulatory documents state that signs of a severe allergic reaction, or hypersensitivity, can include hives (itchy rash), swelling of the face, lips, tongue, or throat, and difficulty breathing. These symptoms require immediate attention from a healthcare provider.


Q: Are there any known long-term side effects from taking Pravacor?

Studies and official information indicate that long-term use has been associated with some rare but serious adverse effects. These include reports of interstitial lung disease (a serious lung condition) and a rare, severe muscle disorder called Immune-Mediated Necrotizing Myopathy (IMNM).


Q: Is it necessary to take Pravacor at the exact same time every day?

Official product information states that the drug is taken once a day. Taking the medication around the same time each day is described as beneficial. This practice helps individuals remember their daily dose and may support consistent management of the condition.


Q: How quickly should I expect to see changes in my cholesterol numbers after starting Pravacor?

According to the official prescribing information, changes in LDL cholesterol levels can typically be assessed after about four weeks of starting treatment. This timeframe is when the effects may be reviewed by a healthcare professional.


Q: How is Pravacor monitored in patients who have a history of liver issues?

Official regulatory guidelines require that liver function tests (specifically measuring serum transaminases) be performed before starting Pravacor therapy. These tests are then repeated periodically thereafter as part of standard monitoring for any potential liver changes.


Q: Why is Pravacor sometimes taken in the evening?

Official patient information suggests that taking the medication in the evening, sometimes before bedtime, may be recommended. This is because the body’s natural production of cholesterol is typically highest during the nighttime hours.


Q: Does taking Pravacor increase the chance of developing diabetes?

Official regulatory documents report that some patients treated with statins, including pravastatin, have shown increases in measures like HbA1c and Fasting Serum Glucose levels. These increases are generally consistent with changes associated with the onset of new diabetes.


Q: Is fatigue or unusual tiredness a frequent side effect of Pravacor?

Official regulatory documentation lists tiredness or fatigue as an occasional or less common adverse reaction. This information is based on data collected during clinical trials and post-marketing experience.


Q: Can Pravacor affect my sleep patterns like causing insomnia or nightmares?

Official regulatory documents include reports of sleep disturbances as a possible adverse reaction. These disturbances can involve both difficulty falling asleep (insomnia) and experiencing bad dreams (nightmares).


Q: Does consuming alcohol affect how Pravacor works or increase side effect risk?

Official patient counseling information indicates that heavy consumption of alcohol is a factor that may increase the risk of developing liver problems, which is a known serious side effect of statin medications.


Q: Is Pravacor a drug that needs to be stopped before surgery or dental procedures?

Official warnings state that Pravastatin should be temporarily discontinued in patients facing major surgery or other acute, serious conditions that put them at risk of developing rhabdomyolysis.


Q: If I feel fine, why is it important to keep taking Pravacor long-term?

Official patient information states the importance of continuous use for the management of the condition, even when a person feels well. This is because it is a long-term control medicine for a condition (high cholesterol) that often has no immediate, noticeable symptoms.


Q: Can Pravacor affect my ability to drive or operate machinery?

According to official product information, the drug is generally considered to have little or no influence on the ability to drive or use machinery. The product information notes that possible adverse effects like dizziness should be considered.


Q: What official research evidence is available for Pravacor's use in primary prevention (patients with high risk but no prior event)?

Official drug labels indicate that Pravastatin is approved for use in certain adult patients who have not yet had established heart disease but possess multiple risk factors. The purpose in this group is to reduce the risk of a first heart attack.

How should Pravacor be stored and disposed of?

Storage Requirements

Pravacor (pravastatin sodium) tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with allowable temperature excursions up to 30 C (86 F). The product must be stored in its original container and the container must be kept tightly closed to maintain product stability.

Environmental Protection and Safety

The tablets must be protected from light and moisture. Consequently, they should be stored away from excessive heat and moisture, such as the bathroom. All medication must be stored safely out of the reach of children.

Disposal of Unused Product

Unused or expired Pravacor must be disposed of in accordance with local regulations. The most environmentally sound method is typically a medicine take-back program. If this option is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed container, and thrown into the household trash, rather than flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pravacor found in:

A-Z Index: